Pfizer pays $250m for OTC Nexium rights
August 14, 2012Sales and Marketing AstraZeneca, EMA, FDA, Nexium, OTC, Pfizer
Pfizer will pay $250 million to AstraZeneca in order to gain the rights to sell an over-the-counter form of the …
Pharma manufacturing news in brief
August 14, 2012Manufacturing and Production Advanced Bioscience, Almac, Amneal, Cipla, Isis, Sanofi Pasteur
Cipla opening three new API plants as Indian trade delegations forges closer ties with Sri Lanka; plus facility updates from …
Amgen unveils plan to close Epogen plant
August 14, 2012Manufacturing and Production Amgen, Epogen, cuts, omontys
Amgen has said it will close down a manufacturing facility in Longmont, Colorado, in the face of declining sales of …
De Facto in management buy out
August 14, 2012Medical Communications Chime Communications, De Facto Communications
Healthcare and life sciences communications specialist De Facto Communications has completed a management buyout of the business from Chime Communications.The …
WuXi continues strong growth
August 14, 2012Manufacturing and Production China, WuXi
Chinese contract research firm Wuxi saw its revenue grow strongly in the second quarter, with its laboratory services playing a …
Avastin sees success in brain cancer trial
August 13, 2012Research and Development, Sales and Marketing R&D, avastin, brain cancer
A late-stage study has shown that Roche’s oncology drug Avastin, when added to standard therapy, can help people with brain …
Torisel-Avastin combo fails in kidney cancer
August 13, 2012Research and Development, Sales and Marketing R&D, Sutent, Torisel, avastin, failure, rcc
Combining Pfizer’s Torisel and Roche’s Avastin does not increase survival rates for advanced kidney cancer patients. This is according to …
Lucentis gains new licence in the US
August 13, 2012Sales and Marketing Eylea, FDA, Lucentis, approval, avastin, wet AMD
Roche’s eye drug Lucentis has gained a new licence in the US to treat diabetic macular oedema. The FDA has …
Contract research news in brief
August 10, 2012Research and Development Accenture, Charles River Labs, ICON, Octagon Research Solutions, Phlexglobal, Quanticate, Verum
ICON plans UK investment, Verum expands in the US, plus updates from Charles River, Phlexglobal, Accenture/Octagon and Quanticate.
Merck Serono says dispute over Geneva closure is resolved
August 10, 2012Manufacturing and Production Geneva, Merck Serono, Quintiles, cuts
Merck Serono says it has reached agreement with groups representing workers affected by the closure and downsizing of sites in …
FDA approves leukaemia drug Marqibo
August 10, 2012Sales and Marketing FDA, Marqibo, Talon Therapeutics, lilly
The Food and Drug Administration has given the green light for Talon Therapeutics’ Marqibo to combat a rare form of …
Pfizer signs drug profiling deal with Nodality
August 10, 2012Research and Development, Sales and Marketing Lupus, Nodality, Pfizer, SCNP
Pfizer has signed a multi-year drug profiling deal with Nodality to help get the best from its autoimmune disease compounds. …
Former Pfizer head Kindler joins Lux Capital
August 10, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kindler, Pfizer
Venture capital firm Lux Capital has appointed former Pfizer chairman and chief executive Jeff Kindler as a partner. Kindler will …
Fuji buys Thai manufacturing facility from DKSH
August 9, 2012Manufacturing and Production DKSH, Fuji, OLIC, Thai
Japan’s Fuji Pharma has bought Thailand’s largest pharmaceutical contract manufacturing organisation OLIC from current owner DKSH. In a deal that …
Working Life: Amanda Paxon
August 9, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amanda Paxon, Boehringer Ingelheim, Working Life
How did you find your way into your current role? Through a combination of good luck and hard work! I …
NICE still minded not to recommend Zelboraf
August 9, 2012Sales and Marketing BMS, NICE, QALY, Yervoy, Zelboraf
NICE is asking Roche for more information about its melanoma pill Zelboraf, saying it is still too expensive and its …
Amgen scraps pancreatic cancer drug
August 9, 2012Research and Development, Sales and Marketing Amgen, GAMMA, Ganitumab, pancreatic
Biotech company Amgen has abandoned its late-stage trial of a new drug for one of the most hard-to-treat of all …
Nicholson to end NHS black listing of drugs
August 9, 2012Sales and Marketing IHW, NHS, NICE, Sir David Nicholson, formulary
The chief executive of the NHS is looking to stamp out black listing of NICE-approved medicines. In a letter to …
Cambridge University gains stem cell centre funding
August 9, 2012Research and Development, Sales and Marketing Cambridge, MRC, Wellcome Trust, stem cell
The Wellcome Trust and the Medical Research Council are investing £8 million into a new stem cell research centre. The …
UK government to create four new ‘eHealth’ centres
August 9, 2012Sales and Marketing MRC, NHS, data, eHealth, investment, patient records
A consortium of ten UK government and charity groups has invested £19 million to create a series of eHealth research …
Latest content
Highlighting the value of lab research for healthcare innovation
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
